CS First Boston Says Inventories Could Hurt Tellabs Sales

Analyst James Parmelee says there could be additional down side to the stock

CS First Boston analyst James Parmelee says that he sees significant risk to his near term sales estimates for Tellabs (TLAB ) based upon a lengthened time to work down Titan 5500 inventories. The analyst said that with the timing of the recovery less clear, his near term sales estimates of $780 million for the second quarter and $890 million for the third quarter may need to be reduced.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.